title: Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease.
abstract: OBJECTIVE
  To describe 3 cases of scleritis associated with etanercept use for rheumatoid arthritis (RA) and to review the literature related to inflammatory eye diseases associated with the use of etanercept.
  
  
  METHODS
  Three cases of severe scleritis during etanercept therapy were analyzed. A systematic review of the literature in PubMed, Embase, and the Cochrane Library was performed, from 1962 to July 2010.
  
  
  RESULTS
  Three patients with seropositive RA developed scleritis 7-28 months after initiation of etanercept, for the first time during their long-lasting disease. In all patients the underlying disease had responded well to anti-tumor necrosis factor therapy. Ocular inflammation went into remission after discontinuation of etanercept, and no other relapses were observed. One patient experienced a dechallenge-rechallenge phenomenon (improvement in symptoms following discontinuation of the agent, then reappearance or worsening of symptoms on reexposure to the agent). Forty-two cases of inflammatory eye diseases believed to be associated with the use of etanercept have been reported in the literature: 33 uveitis, 8 scleritis, 1 orbital myositis, concerning 16 patients with RA, 10 with juvenile idiopathic arthritis, 14 with ankylosing spondylitis, and 2 with psoriatic spondyloarthropathy. Dechallenge was performed in 28 patients, leading to resolution of symptoms. Rechallenge was done in 6 cases, with clear exacerbation.
  
  
  CONCLUSIONS
  Ocular inflammation is paradoxically a potential adverse effect of etanercept, even in previously uninvolved eyes.
authors.affiliation: Pierre et Marie Curie University, AP-HP, Department of Rheumatology, Pitié-Salpêtrière Hospital, [corrected] Paris, France. cecile.gaujoux-viala@psl.aphp.fr
authors.forename: Cécile
authors.initials: C
authors.lastname: Gaujoux-Viala
authors.forename: Cecilia
authors.initials: C
authors.lastname: Giampietro
authors.forename: Thomas
authors.initials: T
authors.lastname: Gaujoux
authors.forename: Hang-Korng
authors.initials: HK
authors.lastname: Ea
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
authors.forename: Philippe
authors.initials: P
authors.lastname: Orcel
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Frédéric
authors.initials: F
authors.lastname: Lioté
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab; D015423:Scleritis / Q000139:chemically induced*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D000068879:Adalimumab; D000068800:Etanercept